Amlogenyx Inc

BEVERLY HILLS, Calif.--( BUSINESS WIRE )--GordonMD ® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), is researching and developing novel gene therapies for Alzheimer’s disease and other amyloid diseases. “I am pleased to collaborate with Amlogenyx; its promising Alzheimer’s disease therapeutic has yielded exciting results in pursuing a therapy that has the potential to change the outlook for this disease,” said Dr. Craig Gordon, Founder and Chief Investment Officer of GordonMD ® . “Amlogenyx’s first product candidate is a protease that we developed alongside Sandra D’Azzo Ph.D. at St. Jude Children’s Research Hospital in Memphis,” said Emil Kakkis, M.D., Ph.D., CEO of Ultragenyx. “The study found that the enzyme can break up and degrade efficiently Aβ42, the protein many consider responsible for Alzheimer’s debilitating effects.” The seed round was led by GordonMD ® and associated investors, as well as Ultragenyx. About GordonMD ® Global Investments GordonMD ® Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with more than 13 years of buy-side experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan. It currently provides investment management and administrative services to a hedge fund investing primarily in publicly traded companies as well as to two private equity funds.

SAN FRANCISCO — Ultragenyx, the commercial-stage California biotech working on ultra-rare diseases, is finishing up a $50 million Series A fundraise for its Alzheimer’s gene therapy spinout, named Amlogenyx, CEO Emil Kakkis told Endpoints News. “We have a lead investor signed on, and we have several investors who are on board. We’re still trying to fill out a $50 million syndicate,” Kakkis said on the sidelines of this year’s JP Morgan Healthcare Conference on Monday. “We have most of it, or a good part of it, so we’re trying to get the last two, three people to finish it.”

Ultragenyx will spin out a new company to take advantage of research it claims could lead to a new way of treating Alzheimers disease.Researchers working for the company found that an enzyme called protective protein/cathepsin A, or PPCA, can break up a form of amyloid beta, the protein many consider responsible for Alzheimers debilitating effects. Initial mouse studies were encouraging, Ultragenyx told investors Monday.CEO Emil Kakkis called the finding too important not to pursue, but the work and funding needed to develop an Alzheimers drug is well outside of Ultragenyxs rare disease focus. So, Ultragenyx is forming a new company called Amlogenyx to capitalize on the high-risk, high return discovery.I couldn't sit by and watch something this exciting and not actually put it into play, Kakkis told investors. I can see this just being a leap ahead of how you might treat Alzheimer's.Ultragenyx will maintain majority ownership in the new company and seek independent funding for it, with the goal of closing a Series A financing by the end of the year. The spinout will be cash neutral for Ultragenyx, Kakkis said.Kakkis described the work until now as low-key, with a small amount of money spent on research. Ultragenyx will grant the new company a license for the required intellectual property and know-how, allowing it to use Ultragenyxs Pinnacle PCL manufacturing platform.The announcement came as part of Ultragenyxs investor day program, though the company didnt flag the spinout in its press release. Kakkis laid out the details toward the end of a slideshow presentation.Researchers have long focused on clearing amyloid plaques in the brain as a way of battling Alzheimers, even though some experts have questioned the approach. Despite decades of work and billions of dollars, there is no cure for the disease.The Food and Drug Administration has approved two drugs designed to slow Alzheimers progression by targeting amyloid plaques. The first, Biogens Aduhelm, was embroiled in controversy amid questions about how much it benefits patients. Biogen later stopped marketing it. The second, a drug called Leqembi developed by Eisai and Biogen, may prove more successful after initial pushback from insurers before its full approval in July. The data supporting it are clearer in showing a benefit to treatment.A third, similarly acting drug, called donanemab and from Eli Lilly, could receive an FDA approval by the end of the year.Still, the effects of these monoclonal antibody drugs are modest, Kakkis said. The Amlogenyx gene therapy approach, which would use a viral vector to deliver the PPCA enzyme, may provide better potency, he said. '